Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RSV/hMPV/PIV3 vaccine - Sanofi

Next Previous
X
Search
Drug Profile

RSV/hMPV/PIV3 vaccine - Sanofi

Alternative Names: Trivalent RSV-hMPV-PIV3 vaccine - Sanofi

Latest Information Update: 11 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 23 Sep 2024 Sanofi plans a phase I trial for Metapneumovirus infections, Parainfluenza virus infections and Respiratory syncytial virus infections (Prevention, In adults, In the elderly) (IM), September 2024 (NCT06604767)
  • 19 Sep 2024 Preclinical trials in Metapneumovirus infections (Prevention) in France (IM), prior to September 2024
  • 19 Sep 2024 Preclinical trials in Parainfluenza virus infections (Prevention) in France (IM), prior to September 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top